Halozyme Therapeutics (HALO) EBIT Margin (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of EBIT Margin data on file, last reported at 48.98% in Q1 2026.

• On a quarterly basis, EBIT Margin fell 446.0% year-over-year to 48.98% in Q1 2026; TTM through Mar 2026 was 33.94%, a 2116.0% decrease from a year earlier, with the FY2025 full-year figure at 33.58%, down 2073.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 48.98%, up from 20.56% in the prior quarter.
• Over the last five years, EBIT Margin for HALO reached as high as 64.52% in Q1 2022 and fell as low as 20.56% in Q4 2025.
• Historically, EBIT Margin has averaged 44.04% across 5 years, with a median of 48.78% in 2024.
• Across the five-year window, EBIT Margin surged 2038 bps in 2023 and sank 7945 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 41.05% in 2022, then gained by 7 bps to 43.92% in 2023, then soared by 34 bps to 58.89% in 2024, then tumbled by 135 bps to 20.56% in 2025, then soared by 338 bps to 48.98% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 48.98% in Q1 2026, 20.56% in Q4 2025, and 61.51% in Q3 2025.